Biotron Share Price Up as it Responds to ASX Query

By ,

The share price of Biotron [ASX:BIT] is up 9.5% and trading at $0.115, at time of writing.

It has been an exciting time for Biotron shareholders who, last month, could have sold their shares for a whopping $0.445.

The stock has since fallen dramatically, but still has a one-year return of 262%:

biotron price market index

Source: marketindex.com.au

Biotron is a biotechnology research company working on a range of antiretroviral drugs.

Antiretroviral drugs fight viruses, and Biotron has recently had a positive drug trial result for its HIV medication.

The latest news out of the company driving the price higher today is its response to an ASX aware letter.

Interested in bio-tech stocks but don’t know where to start? We’ve got a free report available here, that guides you through making the best picks.

Biotron responds to ASX aware letter

ASX aware letters are a way for the ASX to query companies about the timing of market sensitive announcements:

When ASX has concerns about whether an entity has disclosed market sensitive information at the time it should have under Listing Rule 3.1, it will typically issue an ‘’aware letter” to the entity. The purpose of an aware letter is to enable ASX to be satisfied that the entity is in compliance with its continuous disclosure obligations.’

In the aware letter in question, the ASX posed a number of questions to the company, asking for it to expand on its initial press release.

Biotron responded with a significant volume of detail about its trial program, outlining the specifics of its Phase 2 trial.

Biotron withholds some information from ASX

Certain details were not disclosed however, such as:

Detailed analyses and graphs from the sCD163 and the flow cytometric analyses have not been released to the market, as they remain trade secrets and subject to strict confidentiality … until presented at upcoming scientific conference(s) in the USA in late 2018/2019. Details of the date, time and location of presentation(s) will be released to the market when they are available.’

In essence, Biotron is withholding more information because of the sensitive commercial environment it operates in.

Biotech is a notoriously cutthroat industry, where patents can generate billions of dollars.

Amgen in the US, for example, built an empire off of the success of a single drug — Epogen.

Given the recent volatility in Biotron’s share price, and the lack of updates until it presents its findings, it could remain volatile for the foreseeable future.

Regards,

Lachlann Tierney

PS: Learn how to pick the best bio-tech stocks with our free report. The download is available right here.

About Lachlann Tierney

Lachlann Tierney is an Analyst for Money Morning and has been investing for nearly a decade. With a Masters of Science from the London School of Economics, he brings a sound understanding of global markets to his writing. Lachlann is interested in emerging technologies, energy solutions and helping people invest…

Biotron Share Price Shoots 26% Higher on Preliminary COVID-19 Results

The hunt for a COVID-19 vaccine is ramping up. We learnt yesterday that the government has spent $1.7 billion on potential treatments. Hedging their bets on some $84 million worth of doses that will be ready for free rollouts by 2021…

Three Stocks to Watch during the Coronavirus Rollercoaster

Market volatility is continuing to rise amidst the ongoing global pandemic. Worst yet, it is difficult to pinpoint when this is likely to end. Markets are up one day and crashing down the next. It is a telling sign when investors begin to look for safety among some of Australia’s most speculative small-caps…

A Look at the Orthocell Share Price: Can It Keep Going Up? 

Despite a recent pullback, it has been an exciting ride for investors with the Orthocell share price going through the roof on 8 May .Today we will be looking at what caused Orthocell’s remarkable rise and its prospects going forward. 

Biotron Share Price Up, Letter to Shareholders Includes Useful Information

Early this morning, the share price of Biotron Limited [ASX:BIT] managed to spike up 7.69%, trading at 14 cents per share. In a letter to the shareholders, the company disclosed a couple of useful pieces of information.

Biotron Share Price Volatile as Investors Digest Latest Release

It’s been a rollercoaster ride for the Biotron Limited [ASX:BIT] share price, with the stock up 14.82% today, trading at $.155 at time of writing. Reasons for the current volatility are hard to pin down, but profit-taking and new data released by the company could be factors. The Biotron share price is down from a high of … Read More

Huge Gains for Biotron Share Price After Promising HIV Drug Trial Results

In just the past three trading days Biotron Limited [ASX:BIT] has rocketed up. As at time of writing, it’s trading at $.093, a 489% increase from three trading days ago where it closed at $.019. Biotron is a biotechnology research company working on a range of antiretroviral drugs. Antiretroviral drugs fight viruses, and Biotron has … Read More